Sign In
Buy HIMS
$27.51
+0 (+0%)
At Close: Jun 03, 2026
Hims & Hers to stop offering compounded semaglutide pill after FDA crackdown
02:18pm, Saturday, 07'th Feb 2026
Hims & Hers said in a statement on Saturday that it will stop offering access to the compounded semaglutide pill after the U.S. Food and Drug Administration said it would take action against the teleh
FDA and HHS Hammer Hims & Hers In Compounded Drug Crackdown
09:03am, Saturday, 07'th Feb 2026
Hims & Hers ( NYSE:HIMS ) shares are plunging 16% in after-hours trading following coordinated moves by two federal agencies against its compounded weight-loss drugs.
Weekend Morning Brew: Big Tech's $650B AI Bet, Bitcoin Slides
07:37am, Saturday, 07'th Feb 2026
Weekly Market HighlightsMarket breadth was slightly positive on the week, with 4,831 advancers versus 4,694 decliners.Returns were highly skewed, with 491 stoc
Health Regulators Ask DOJ to Investigate Hims & Hers. The Stock Plunges.
08:25pm, Friday, 06'th Feb 2026
Shares of Hims & Hers Health tumbled more than 12% on Friday in after-hours trading, as the company faced increased scrutiny from federal regulators.
FDA Targets Hims & Hers, Other Marketers of Unapproved GLP-1 Weight-Loss Drugs
06:23pm, Friday, 06'th Feb 2026
The FDA said “decisive steps” will be taken to restrict drugs using GLP-1 active pharmaceutical ingredients in non-approved drugs.
Market Today: Dow tops 50,000 as chip leaders rebound; Stellantis plunges
05:35pm, Friday, 06'th Feb 2026
Guru Stock PicksTom Gayner has made the following transactions:Reduce in ADI by 12.37%Sold out in ADBEAdd in TMO by 12.54%New position in BRORichard Pzena has m
Hims & Hers stock nears one-year low amid battle over compounded Wegovy pill
03:29pm, Friday, 06'th Feb 2026
Hims & Hers also said it's selling a cancer-detection test that's featured in its Super Bowl ad, which plays like a commentary on the wealthy's access to better healthcare.
Wall Street Roundup: Risk Off
01:25pm, Friday, 06'th Feb 2026
Risk-off sentiment is driving sharp sell-offs in Bitcoin and major software stocks, with investors reallocating away from stretched tech valuations. AI-driven CapEx arms race at Alphabet (GOOGL) and A
Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
01:14pm, Friday, 06'th Feb 2026
Hims & Hers' gambit to sell a $49 compounded version of Novo Nordisk's Wegovy pill is rattling obesity shares, sparking debate about the legality of the move and threatening drugmaker returns in the b
Hims & Hers Strengthens Platform-Led Digital Healthcare Model
11:31am, Friday, 06'th Feb 2026
HIMS is scaling a platform-led digital healthcare model with Labs, AI and YourBio Health, integrating diagnostics, data and care into one ecosystem.
Novo Nordisk Shares Slide 21% After Forecast Cut, Copycat Wegovy Pill Launch
10:41am, Friday, 06'th Feb 2026
Novo Nordisk A/S (NVO) shares have come under renewed pressure after a short-lived rebound earlier this year gave way to a sharp shift in investor sentiment. Af
Hims & Hers falls ~8% premarket after FDA warning on copycat drugs
10:37am, Friday, 06'th Feb 2026
Shares of Hims and Hers Health (HIMS) came under renewed pressure Friday, falling roughly 8% in premarket trading after FDA Commissioner Marty Makary said the age
NVO, LLY Stocks Slide as HIMS Launches $49 Compounded Semaglutide Pill
10:30am, Friday, 06'th Feb 2026
HIMS shakes up the weight loss market with a $49 compounded semaglutide pill, pressuring Novo Nordisk and Eli Lilly shares and sparking FDA and legal pushback.
Major stock indexes opened higher Friday, a day after equities sank amid risk-off sentiment. Still, the Nasdaq and S&P 500 were poised to register sharp weekly losses.
First Look: Amazon's $200B AI Bet, Tech Rout
07:37am, Friday, 06'th Feb 2026
Stock News Amazon hikes AI capex: Amazon (AMZN) warned 2026 capital expenditures will surge to about $200 billion, focused largely on AWS and AI infrastructure,
